arrow
D

Daniel Egle

Medical University Innsbruck
H指数:32
被引数:5,784

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The Xpert Breast Cancer Insight Test Predicts Distant Recurrence and Overall Survival in ER-Positive, HER2-Negative Early Breast Cancer

Xpert乳腺癌洞察测试可预测ER阳性、HER2阴性早期乳腺癌的远处复发和总生存期

2026-07-010
OAAI
Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive/HER2-negative advanced breast cancer: a real-world multicenter cohort study from Austria

整合基线ctDNA衍生的肿瘤指标可增强HR阳性/HER2阴性晚期乳腺癌的风险分层:一项来自奥地利的真实世界多中心队列研究

2026-03-310
OAAI
Dynamic Contour Irregularities in Implant-Based Breast Reconstruction: Long-Term Aesthetic Outcomes After Direct-to-Implant Versus Tissue Expander Techniques

基于植入物的乳房重建中的动态轮廓不规则性:直接植入法与组织扩张器技术长期美学效果的比较

2025-11-280
OAAI
Palbociclib with adjuvant endocrine therapy in early breast cancer: five-year follow up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)

帕博西利联合辅助内分泌疗法在早期乳腺癌中的应用:全球多中心、开放标签、随机III期PALLAS试验(ABCSG-42/AFT-05/PrE0109/BIG-14-13)五年随访分析

2025-10-170
OAAI
Plain language summary of publication: Comparing nivolumab and neoadjuvant chemotherapy with placebo and neoadjuvant chemotherapy in participants with newly diagnosed estrogen receptor-positive breast cancer in the CheckMate 7FL clinical trial

出版物简明摘要:比较在CheckMate 7FL临床试验中,对于新诊断的雌激素受体阳性乳腺癌患者,使用纳武利尤单抗联合新辅助化疗与安慰剂联合新辅助化疗的疗效。

2025-10-010
PRE
Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer

肿瘤特异性主要组织相容性-II表达预测三阴性乳腺癌中阿替利珠单抗联合化疗的病理完全缓解

2025-09-290
OAAI
Genomic profiling of primary tumor and lymph node metastasis in patients with clinically node-positive breast cancer: prospective cohort study within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57–18, ABCSG-53, GBG 101)

临床淋巴结阳性乳腺癌患者原发肿瘤和淋巴结转移的基因组分析:TAXIS(OPBC-03、SAKK 23/16、IBCSG 57–18、ABCSG-53、GBG 101)框架下的前瞻性队列研究

2025-06-180
PRE
Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trials
BREAST
IF7.9
2025-04-010
OAAI
Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer
2025-03-010
PRE
Identification of differentiating sonographic features between fibroadenomas and malignant tumors of the breast mimicking fibroadenomas: 10-year experience in 421 histologically verified cases

鉴别纤维腺瘤和模仿纤维腺瘤的乳腺恶性肿瘤之间的超声特征: 421例经组织学证实的病例的10年经验

2025-02-040
OAAI
HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: potential for biomarker-driven sequencing of T-DXd and HER3-DXd

HER2和HER3在HER2阴性早期乳腺癌新辅助治疗期间的表达:T-DXd和HER3-DXd生物标志物驱动的序贯治疗的潜力

2025-01-060
PRE
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024-09-231
OAAI
Cropsi study: Efficacy and safety of cryotherapy and cryocompression in the prevention of chemotherapy-induced peripheral neuropathy in patients with breast and gynecological cancer-A prospective, randomized trial

Cropsi研究: 冷冻疗法和冷冻压缩疗法在预防乳腺癌和妇科癌症患者化疗引起的周围神经病变中的疗效和安全性-一项前瞻性随机试验

BREAST
IF7.9
2024-08-012
OAAI
Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting? (Jan, 10.1007/s10549-023-07186-6, 2024)
2024-05-050
OAAI
Change of first-line treatment pattern in metastatic luminal breast cancer: Results from the Austrian AGMT_MBC-Registry
2024-05-020
PRE